/Investor DB

Vivo Panda

Venture capital

Palo Alto · 2 people tracked

Find your way into Vivo Panda

Sign up to see every warm intro you have to Vivo Panda

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Vivo Panda team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

✨ Fox Verdict
Sign up to see your fit

Fund manager profile

Vivo Panda is a venture fund manager based in Palo Alto. SEC filings show 1 venture fund on record, most recently Vivo Panda Fund, L.P. ($100.3M offering) filed June 2016.

Source: SEC EDGAR Form D filings. Firm website data not yet available.

HQ
Palo Alto, US
Founded
2016
Tracked investments
2
IPOs
1

Team · 2 people

from public directories

What they invest in

from 2 of 2 portfolio companies

Biotech ×2Healthtech ×2

Investments · 2 tracked

founders shown can be your intro path
Q32 Bioq32bio.comin𝕏NASDAQ: QTTB

Q32 Bio is a biotechnology company developing therapies for autoimmune and inflammatory diseases, with a scientific focus on the complement system and immune regulation in conditions such as inflammation, autoimmunity and fibrosis.

BiotechHealthtech

Shelia Violette(Founder & Chief Scientific Officer)inMichael Holers(Co-founder)Jodie Morrison(Chief Executive Officer)inLee Kalowski(President & Chief Financial Officer)Maria Marzilli(Chief Business Officer)inDavid Appugliese(Senior Vice President, Head of People)in

Co-investorsAtlas VentureOrbiMedAgent CapitalCU Healthcare Innovation FundOUP (Osage University Partners)Sanofi Ventures+2 more

Verona Pharmaveronapharma.cominJul 2020SEC filingmedium confidence

Verona Pharma develops treatments for chronic lung conditions.

BiotechHealthtechLondon

Jan-Anders Karlsson(Executive Officer, Director)inPeter Spargo(Executive Officer)inPatrick Humphrey(Director)Ken Cunningham(Director)Kenneth Newman(Executive Officer)Anders Ullman(Director)

Board seatMahendra Shah· per SEC Form D · $200.2M raise · filed Jul 2020

Co-investorsAccess BiotechnologyAisling CapitalAndera PartnersForesite CapitalFrazier Life SciencesNew Enterprise Associates (NEA)+4 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 1

1 IPOs

Q32 BioNASDAQ: QTTB

Portfolio news

latest coverage across their companies

IPO stake values · per SEC filings

Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.

CompanyOwnedIPO priceAt IPOStake value
Q32 Bio1.8%$16.00Mar 2018$10.6M

Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).

Frequently asked questions

Where is Vivo Panda located?
Vivo Panda is headquartered in Palo Alto, US.

Featured in lists